MODERNA BIOTECH MANUFACTURING UK LTD

• ◆

  Outstanding charges registered

  One or more mortgages or charges remain undischarged on the Companies House register.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +912.2%

  £4,687,888 → £47,450,009

• Cash

  +111.8%

  £6,521,457 → £13,812,466

• Net assets

  +115.6%

  £30,447,033 → £65,648,265

• Employees

  +1,575%

  4 → 67

• Operating profit

  -354.5%

  £76,758 → -£195,315

• Profit before tax

  -1,141.8%

  -£276,736 → -£3,436,439

• Wages

  +1,223.6%

  £798,490 → £10,569,084

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“received written support from its parent and ultimate parent to maintain going concern status through at least December 2026. ... Based on the liquidity of the Group and future forecasts, the directors believe that the Group has sufficient liquidity to meet the Company's short and medium-term business needs and obligations. ... the directors continue to adopt the going concern basis in preparing the financial statements.”

Significant events

• “On 1 January 2024, a group of 26 UK-based employees was transferred from Moderna Biotech Distributor UK Ltd to Moderna Biotech Manufacturing UK Ltd under the Transfer of Undertakings (Protection of Employment) Regulations 2006 (TUPE).”
• “The Company achieved Facility Readiness in September 2025, triggering an £80 million milestone payment under its agreement with the UK Government.”
• “Construction of the R&D building was completed in April 2025, and the drug substance manufacturing building was finalized in September 2025.”
• “The Company's loan facility was expanded to £200 million during the year to further support its operational and strategic objectives.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.